Project Grant R01HL171156
Award Date 8/15/25
Completion Date 5/31/29
Dollars Obligated $725K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $790,498 to the University of Southern California (USC) for a research project entitled "Targeting PCBP1 to Ameliorate Pathological Angiogenesis". The grant, which runs from September 1, 2025 to June 30, 2030, aims to investigate the role of the PCBP1 protein and its target AARS2 in regulating vascular endothelial growth factor (VEGF) signaling and...
- This $750,345 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Pittsburgh. The funding supports research to investigate the role of telomerase reverse transcriptase (TERT) in the osteogenic reprogramming of aortic valve interstitial cells, which can lead to calcific aortic valve disease. The project aims to elucidate the epigenetic and transcriptional changes directed by...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to support research on modulating the resolution of angiogenesis and normalizing the vasculature for therapeutic benefit in cardiovascular diseases. The $549,665 award, effective January 15, 2025 through November 30, 2028, will fund research conducted by the University of Maryland, Baltimore to investigate mechanisms that regulate the resolution of angiogenesis,...
- The federal Project Grant award of $535,556.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Alabama at Birmingham (UAB). The funding will support a research project to investigate the role of a novel histone modification, H3T32 O-GlcNAc, in endothelial cell dysfunction and atherosclerosis. The 5-year project aims to elucidate the epigenetic features of this histone modification under...
- The University of Rochester was awarded a $226,101 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on pulmonary angioblasts and their role in vascular development. The project aims to leverage existing single-cell RNA sequencing data to uncover novel insights into the cellular characteristics and regulatory mechanisms governing pulmonary angioblasts, which are critical for vascular regeneration and the...
- This $607,952 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pittsburgh to investigate indole metabolites as novel danger signals that activate regulated cell death pathways in lung epithelial cells, which may contribute to the pathogenesis of acute respiratory distress syndrome (ARDS). The key research objectives include...
- This federal Project Grant award of $1,119,410.00 was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports a multi-disciplinary research initiative to investigate longitudinal changes in DNA methylation (LC-DNAM) and its relationship to cardiovascular disease (CVD) risk factors and outcomes across four large population-based cohort studies - ARIC, CARDIA, FHS, and MESA. The research aims to: 1)...
- The federal Project Grant award, titled "Focal Myocardial Delivery of Small Molecule Nitroalkenes Using Ultrasound Targeted Microbubble Cavitation to Improve Ventricular Recovery Following Myocardial Infarction," was awarded by the National Heart Lung and Blood Institute under CFDA 93.837, the Cardiovascular Diseases Research program. The $720,676 award, with a start date of March 4, 2025 and an ultimate completion date of December 31, 2028, aims to develop a novel therapeutic strategy...
- This federal Project Grant award of $740,037, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the regulation of angiogenesis (blood vessel formation) by cardiac fibroblasts following myocardial infarction. The key objectives are to investigate the temporal and spatial expression of pro- and anti-angiogenic factors secreted by cardiac fibroblasts to support cardiac repair and increase vascular...
- This Project Grant award of $636,982.00 was provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to comprehensively investigate the proteolytic mechanisms that govern factor VIII regulation before and after activation, which is critical for maintaining normal blood clotting and preventing bleeding disorders like hemophilia A. The project aims to understand how proteolysis of factor...